Shanghai, China, May 14, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has been included in the MSCI Global Small Cap Indexes following the results of the MSCI Equity Indexes May 2025 Index Review. The inclusion will be implemented as of the close of May 30, 2025.

On 12 May 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) announced that the self-developed innovative drug FCN-159 tablets (Luvometinib tablets, hereinafter the “New Drug”) has been granted breakthrough therapy designation for the treatment of children with Langerhans cell histiocytosis by the National Medical Products Administration (the “NMPA”). Currently, the New Drug is at the stage of Phase II clinical trial in Chinese Mainland.

As integration progresses within the Guangdong-Hong Kong-Macao Greater Bay Area, cross-border mobility and demand for medical services continue to rise. In recent years, residents have shown increasing concern for “seamless healthcare access”, “high-quality medical services”, and “direct payment options for medical expenses”.

During the May Day holiday, domestic travel consumption surged, with Fosun Tourism Group’s vacation products achieving full occupancy across multiple resorts and destinations, solidifying its leadership in the leisure travel sector

On April 29, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) announced a licensing agreement with Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, granting exclusive commercialization rights for its self-developed ipilimumab biosimilar HLX13 in the United States, 42 European countries and regions, Japan, Canada, and Australia.

Fakeeh Care Group has announced a strategic partnership with Fosun Pharma, a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. This partnership is part of Fakeeh Care Group’s ambitious vision to accelerate healthcare innovation in Saudi Arabia and align with the Saudi Vision 2030.

(Hong Kong, 25 April 2025) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), issued the Environmental, Social and Governance (ESG) Report 2024 (the “ESG Report”). Facing the increasingly severe challenges of global climate change, Fosun released its third Climate Information Disclosures Report with reference to the Part D of Appendix C2 of the Main Board Listing Rules (the “New Climate Requirements”) of the Hong Kong Stock Exchange, the Task Force on Climate-Related Financial Disclosures (TCFD) recommendations and International Financial Reporting Standards S2 Climate-related Disclosures Requirements (“IFRS S2”).

(April 25, 2025, Shanghai, China) April 25 is World Malaria Day. The World Health Organization (WHO) theme for the 2025 World Malaria Day is Malaria Ends With Us: Reinvest, Reimagine, Reignite, aiming to re-energize efforts at all levels, from global policy to community action, to accelerate progress towards malaria elimination.

On 24 April 2025, Nanyang Commercial Bank (“NCB”) and Fosun International Limited (“Fosun International”, HKEX stock code: 00656) entered into a strategic cooperation agreement.